ESCC
Clinical trials for ESCC explained in plain language.
Never miss a new study
Get alerted when new ESCC trials appear
Sign up with your email to follow new studies for ESCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to shrink esophageal tumors before surgery
Disease control Not yet recruitingThis study tests a new combination of two antibodies (iparomlimab and tuvonralimab) plus chemotherapy before surgery for people with a type of esophageal cancer that can be removed. The goal is to see if this treatment can completely or mostly eliminate the tumor before surgery. …
Matched conditions: ESCC
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 03:58 UTC
-
New drug combo may let some esophageal cancer patients skip surgery
Disease control Not yet recruitingThis study tests a drug called adebrelimab combined with chemotherapy before either watchful waiting or surgery for people with a type of esophageal cancer. About 200 participants will receive the treatment first. If their cancer disappears completely, they will be randomly assig…
Matched conditions: ESCC
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 03:58 UTC
-
Promising drug cocktail aims to shrink esophageal tumors before surgery
Disease control Not yet recruitingThis study tests whether giving a combination of three drugs (adebrelimab, nimotuzumab, and chemotherapy) before surgery can help people with a type of esophageal cancer. The goal is to see if the tumor shrinks or disappears completely before the operation. About 22 adults with r…
Matched conditions: ESCC
Phase: NA • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 03:55 UTC
-
New triple therapy hopes to outsmart tough esophageal cancer
Disease control Not yet recruitingThis study tests a new combination of drugs for people with advanced esophageal squamous cell carcinoma (a type of throat cancer). The three drugs include a targeted therapy (becotatug vedotin), an immunotherapy (tislelizumab), and standard chemotherapy. The goal is to see if thi…
Matched conditions: ESCC
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New combo therapy targets tough esophageal cancer cases
Disease control Not yet recruitingThis study tests a combination of two drugs (SHR-1701 and liposomal irinotecan) in 33 adults with esophageal squamous cell carcinoma who have already received immunotherapy. The goal is to see if the combination can shrink tumors or slow disease progression. Participants will rec…
Matched conditions: ESCC
Phase: PHASE2 • Sponsor: Zhigang Li • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New combo therapy aims to extend life in elderly esophageal cancer patients
Disease control Not yet recruitingThis study tests a combination of the chemotherapy drug TAS-102 and radiation therapy in people aged 65-85 with advanced esophageal cancer that has not spread widely. The goal is to find the best dose and see if the treatment helps patients live longer and controls the cancer. Ab…
Matched conditions: ESCC
Phase: PHASE1, PHASE2 • Sponsor: Qianfoshan Hospital • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC